The 7 most recent market catalysts affecting $SLN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Silence Therapeutics Prices Upsized $175M Underwritten Public Offering Of 12,962,963 ADSs At $13.50 Per ADS
This headline signifies a significant capital raise for Silence Therapeutics (SLN), providing substantial funding for its operations, likely R&D or clinical trials. The 'upsized' n…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32
Morgan Stanley analyst Michael Ulz has updated his coverage on Silence Therapeutics, maintaining an 'Overweight' rating and raising the price target from $25 to $32. This action si…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 85
Silence Therapeutics Announces Commencement Of Approximately $150M Underwritten Public Offering Of American Depositary Shares
This headline indicates a significant capital raise for Silence Therapeutics (SLN) through a public offering. While it provides crucial funding for R&D and operational expenses, it…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 95
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
Silence Therapeutics reported 'best-case outcome' results from its Phase 2 SANRECO trial for divesiran, a treatment for polycythemia vera. The drug demonstrated strong efficacy, wi…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
Silence Therapeutics shares are trading higher after the company announced topline results from the Phase 2 SANRECO trial met its primary and secondary endpoints.
The headline signifies a major positive corporate catalyst for Silence Therapeutics (SLN). Meeting both primary and secondary endpoints in a Phase 2 trial is a critical milestone, …
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 92
Silence Therapeutics Says Phase 2 SANRECO Trial Of Divesiran In Polycythemia Vera Met Primary Endpoint, 88% Response Rate vs. 19% For Placebo; Phase 3 Seen Starting 1H 2027
This headline represents a major positive catalyst for Silence Therapeutics (SLN). The 88% response rate for Divesiran compared to 19% for placebo in a Phase 2 trial is highly stat…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate
Silence Therapeutics (SLN) announced Q2 earnings per share of $(0.09), which significantly beat the analyst consensus estimate of $(0.15). This represents a substantial improvement…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.